- Home
- EVG vs ACRS Comparison
EVG vs ACRS Comparison
Compare EVG & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVG
- ACRS
- Stock Information
- Founded
- EVG 2005
- ACRS 2012
- Country
- EVG United States
- ACRS United States
- Employees
- EVG N/A
- ACRS N/A
- Industry
- EVG Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- EVG Finance
- ACRS Health Care
- Exchange
- EVG Nasdaq
- ACRS Nasdaq
- Market Cap
- EVG 144.8M
- ACRS 127.6M
- IPO Year
- EVG N/A
- ACRS 2015
- Fundamental
- Price
- EVG $10.95
- ACRS $1.26
- Analyst Decision
- EVG
- ACRS Strong Buy
- Analyst Count
- EVG 0
- ACRS 7
- Target Price
- EVG N/A
- ACRS $10.67
- AVG Volume (30 Days)
- EVG 49.4K
- ACRS 801.8K
- Earning Date
- EVG 01-01-0001
- ACRS 05-08-2025
- Dividend Yield
- EVG 8.68%
- ACRS N/A
- EPS Growth
- EVG N/A
- ACRS N/A
- EPS
- EVG N/A
- ACRS N/A
- Revenue
- EVG N/A
- ACRS $17,777,000.00
- Revenue This Year
- EVG N/A
- ACRS N/A
- Revenue Next Year
- EVG N/A
- ACRS $425.96
- P/E Ratio
- EVG N/A
- ACRS N/A
- Revenue Growth
- EVG N/A
- ACRS N/A
- 52 Week Low
- EVG $9.13
- ACRS $0.95
- 52 Week High
- EVG $10.86
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- EVG 55.12
- ACRS 43.64
- Support Level
- EVG $10.80
- ACRS $1.20
- Resistance Level
- EVG $10.99
- ACRS $1.46
- Average True Range (ATR)
- EVG 0.19
- ACRS 0.11
- MACD
- EVG 0.03
- ACRS 0.02
- Stochastic Oscillator
- EVG 82.14
- ACRS 41.77
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.